Location History:
- Daejeon, KR (2018)
- Gyeonggi-do, KR (2022)
Company Filing History:
Years Active: 2018-2022
Title: Miju Park: Innovator in Antibody Development
Introduction
Miju Park is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of three patents to his name, Park is recognized for his innovative approaches to treating autoimmune diseases and cancer.
Latest Patents
Miju Park's latest patents include the "Anti-VISTA antibody and use thereof" and the "Anti-PD-L1 antibody and use thereof." The first patent relates to an anti-VISTA antibody, which includes an antigen-binding fragment, a nucleic acid coding for the antibody, and a method for preparing it. This invention also encompasses a composition aimed at preventing or treating autoimmune diseases. The second patent focuses on an anti-PD-L1 antibody, detailing its production and potential use in pharmaceutical compositions for cancer treatment. Both patents highlight Park's commitment to advancing medical science through innovative antibody therapies.
Career Highlights
Miju Park is currently employed at Pharmabcine Inc., where he continues to work on groundbreaking research in antibody development. His expertise in this area has positioned him as a key figure in the biotechnology sector. Park's work is instrumental in the ongoing fight against serious health conditions, showcasing his dedication to improving patient outcomes.
Collaborations
Miju Park collaborates with notable colleagues, including Weon Sup Lee and Sang Soon Byun. These partnerships enhance the research and development efforts at Pharmabcine Inc., fostering an environment of innovation and teamwork.
Conclusion
Miju Park is a distinguished inventor whose work in antibody development is paving the way for new treatments in autoimmune diseases and cancer. His contributions to the field are invaluable, and his ongoing research promises to make a significant impact on healthcare.